Skip to main content

Author: Frank Schuler

Artisanal CBD Extracts Display Long-Term Efficacy In Kids With Epilepsy

The World Health Organization estimates that as many as 50 million people worldwide suffer from some level of epilepsy, from mild cases to severe. Nearly four out of every five patients diagnosed with epilepsy live in developing countries.

Epilepsy is a chronic, noncommunicable disease within the brain that affects people of all ages. Unfortunately, many cases go undiagnosed, especially cases involving child patients. Undiagnosed cases make it extremely difficult to provide proper care for the suffering patient.

Fortunately, cannabidiol (CBD) has been found to be effective at treating epilepsy. It’s likely the only form of medicine that can be cultivated and processed all over the globe via the hemp plant. Yet another study has found CBD to be effective at treating kids with epilepsy, this time out of Israel. Below is more information about it via a news release from NORML:

Tel Aviv, Israel: Children with refractory epilepsy respond favorably to long-term treatment with plant-derived CBD extracts, according to data published in Pediatric Neurology.

Israeli researchers assessed the safety and efficacy of artisanal CBD-rich extracts in a cohort of adolescents with treatment-resistant forms of epilepsy. Among patients administered extracts for a period of at least one year, 51 percent experienced a significant decline in seizure frequency. Patients reported only nominal side-effects associated with CBD treatment.

Authors concluded, “Artisanal cannabidiol-enriched cannabis may be an effective and safe long-term treatment for refractory epilepsy.”

In 2018, the US Food and Drug Administration granted market approval to Epidiolex, a prescription medicine containing a standardized formulation of plant-derived cannabidiol for the treatment of two rare forms of severe epilepsy: Lennox-Gastaut syndrome and Dravet syndrome. Shortly after approval, the US Drug Enforcement Administration reclassified Epidiolex to Schedule V of the US Controlled Substances Act — the lowest restriction classification available under federal law.

Full text of the study, “The long-term effectiveness and safety of cannabidiol-enriched oil in children with drug-resistant epilepsy,” appears in Pediatric NeurologyAdditional information on cannabis and epilepsy is available from NORML.

International Researchers Determine Cannabis Rarely Induces Psychosis

One of the oldest and most-popular talking points among cannabis prohibitionists is that cannabis is ‘bad for the brain.’ Cannabis prohibitionists, aided by mainstream media and film, have historically portrayed cannabis users as being completely insane.

Arguably the best example of that is via the 1936 film Reefer Madness, in which many of the actors in the film try cannabis and are instantly thrust into a full-blown psychotic episode. One character even commits suicide in the film ‘due to consuming reefer.’

To be sure, mental health issues are a major concern and not to be taken lightly. With that being said, it’s an enormous disservice to people experiencing mental health issues to falsely place blame on cannabis and essentially issue a misdiagnosis.

Suffering patients of all types deserve to have safe access to effective medicine and to have their health advice based on science, not politics. Several studies have debunked the ‘cannabis makes you crazy’ myth, including a recent one involving a team of international researchers. Below is more information about it via a news release from NORML:

Lausanne, Switzerland: Cannabis consumption rarely triggers episodes of acute psychosis in those without a pre-existing psychiatric disorder, according to data published in the journal Translational Psychiatry.

An international team of researchers from Australia, Switzerland, and the United Kingdom assessed lifetime occurrences of “cannabis-associated psychotic symptoms” (CAPS) requiring hospitalization in a cohort of 233,000 European marijuana consumers.

Authors reported that less than one-half of one percent of subjects reported ever having had such an experience. Those at higher risk for such incidences included younger aged subjects, as well as those with a prior diagnosis of bipolar, anxiety, or depressive disorder, or psychosis.

“Our findings are in line with the idea of a common (genetic) vulnerability representing risk that is shared across psychiatric disorders,” authors determined. They concluded, “Rates of CAPS as observed here are comparable to rates of other drug-induced psychosis, such as alcohol-associated psychosis (around 0.4 – 0.7 percent).”

The study’s findings are consistent with those of a separate paper, published in July in the journal Substance Use & Misuse, which reported that medical cannabis patients are at “low” risk for psychiatric hospitalizations resulting from their marijuana use. In that trial, investigators assessed marijuana-related hospitalizations among a cohort of over 23,000 subjects over a median period of 240 days. During that time, only 26 patients were hospitalized explicitly because of “mental or behavioral disorders due to the use of cannabis.”

The findings push back against high-profile claims from some cannabis reform opponents that marijuana exposure is a frequent trigger for psychosis and other mental health disorders.

Full text of the study, “Rates and correlates of cannabis-associated psychotic symptoms in over 230,000 people who use cannabis,” appears in Translational Psychiatry. Additional information on cannabis and mental health is available from NORML’s white paper, ‘Cannabis, Mental Health, and Context: The Case for Regulation.’

Nearly 10% Of Canadian Cannabis Consumers Engage In Home Cultivation

Cultivating your own cannabis can provide many benefits, with one of the most obvious benefits being cost savings. If someone is knowledgeable and able, they can cultivate their own cannabis for a fraction of what it costs to purchase cannabis from retail outlets.

Another major benefit is controlling what goes into your cannabis. After all, if you cultivate your own cannabis then you know exactly how often it is watered, what the water quality is, and what and when your plants are fed nutrients. There are no mysteries as to what your cannabis contains.

Unfortunately, not everyone has the right to legally cultivate their own cannabis, even in places where legalization measures have been passed. Home cultivation is legal in most of Canada, with some local exceptions which are working their way through legal challenges, and the option appears to be very popular according to newly released data. Below is more information about it via a news release from NORML:

Waterloo, Canada: Approximately ten percent of Canadian cannabis consumers report engaging in home cultivation, according to data published in the journal Addictive Behavior Reports.

Canadian researchers surveyed home cultivation patterns prior to and following the enactment of adult-use legalization in 2018. Under the law, adults in most regions of the country are permitted to grow up to four cannabis plants for their own personal use. (The provinces of Quebec and Manitoba prohibit home cultivation.)

Researchers reported that the percentage of consumers who grew their own cannabis increased from six percent prior to the passage of legalization to nine percent in 2020. Those residing in more rural areas were more likely to home cultivate. Most of those who engaged in home cultivation did not exceed legally imposed plant limits.

“Almost one-in-ten Canadian cannabis consumers reported home cultivation of cannabis in 2020, with modest increases following legalization of non-medical cannabis,” authors concluded. “The uptake of home cultivation is associated with province and cultivation policies; specifically, Manitoba and Quebec, the only provinces to prohibit non-medical home cultivation, reported among the lowest rates. Although the current study reported an increase in home cultivation among past 12-month consumers after legalization, it will be important to see whether rates continue to increase, even as access to legal cannabis and the price of legal cannabis decreases.”

Data from the United States has estimated that fewer than two percent of cannabis consumers acknowledge engaging in home cultivation, although the actual percentage of home growers has likely increased in recent years as more jurisdictions have adopted marijuana legalization policies.

NORML has long advocated that consumers in legal jurisdictions ought to have the option to home cultivate personal use quantities of cannabis, opining: “The inclusion of legislative provisions protecting the non-commercial home cultivation of cannabis serves as leverage to assure the product available at retail outlets is high quality, safe and affordable. Additionally, permitting home cultivation provides adult consumers with an immediate source of cannabis — providing an alternative to the illicit market. Such a source is necessary because it typically takes state regulators several months, or even years, following the law’s enactment to establish licensed retail operators.”

Full text of the study, “Home cultivation across Canadian provinces after cannabis legalization,” appears in Addictive Behavior Reports.

Government Of Canada Launches Legislative Review Of The Cannabis Act

Canada became the second country on earth to pass an adult-use legalization measure back in 2018, and still remains the only G-7 country to make such a public policy change. Uruguay was the first to legalize cannabis for adult-use at a national level in 2013, and Malta passed a limited legalization measure late last year.

Policy and industry observers from around the globe have kept a close eye on Canada since the launch of legalization, and the Canadian government is set to conduct a thorough review of the nation’s cannabis policies. Below is more information about it via a news release from the Canadian government:

OTTAWA, ONSept. 22, 2022 /CNW Telbec/ – Today, the Honourable Jean-Yves Duclos, Minister of Health, and the Honourable Carolyn Bennett, Minister of Mental Health and Addictions and Associate Minister of Health, announced the launch of the legislative review of the Cannabis Act. 

The objective of the Cannabis Act is twofold. First, it aims to protect the health and safety of Canadians while serving as a flexible legislative framework that adapts and responds to the ongoing and emerging needs of Canadians. Second, it provides for the establishment of a diverse and competitive legal industry made up of small and large players to displace the illicit market.

Parliamentarians recognized the need for an early assessment of the Government’s new approach to cannabis control, and included a provision requiring a review in the Act. The review will help ensure that the Act adapts to the current situation and continues to meet Canadians needs and expectations.

An independent Expert Panel, chaired by Mr. Morris Rosenberg, will lead a credible and inclusive review. Mr. Rosenberg is very well positioned to serve as Chair of the Expert Panel, with expertise and experience in the fields of justice, public health and public safety. He also has an informed understanding of the relationships between the Government of Canada, provinces and territories, and Indigenous peoples. We will announce the other four members of the Expert Panel in the coming weeks.

The Panel will provide independent, expert advice to both Ministers on progress made towards achieving the Act’s objectives, and will help identify priority areas for improving the functioning of the legislation. It is stated in the Act that the review should focus particularly on the health and cannabis consumption habits of young persons, the impact of cannabis on Indigenous persons and communities, and the impact of the cultivation of cannabis plants in a housing context. The Panel will broaden that focus to include:

  • Economic, social and environmental impacts of the Act;
  • Progress towards providing adults with access to strictly regulated, lower risk, legal cannabis products;
  • Progress made in deterring criminal activity and displacing the illicit cannabis market;
  • Impact of legalization and regulation on access to cannabis for medical purposes; and
  • Impacts on Indigenous peoples, racialized communities, and women who might be at greater risk of harm or face greater barriers to participation in the legal industry based on identity or socio-economic factors.

The Panel will engage with the public, governments, Indigenous peoples, youth, marginalized and racialized communities, cannabis industry representatives and people who access cannabis for medical purposes to gather their perspectives on the implementation of the Act. The Panel will also meet with experts in relevant fields, such as public health, substance use, criminal justice, law enforcement and health care.

Additionally, the Panel was mandated to apply a sex and gender-based analysis plus lens to their review. This means they will examine the degree to which different sub-groups of the population (for example, women and people of colour) may experience unique or disproportionate effects of Canada’s cannabis control framework based on identity or socio-economic factors. The Panel will also examine the medical access framework in the context of the legalization of cannabis, and more specifically, whether all elements of the medical framework are required to maintain reasonable access to cannabis for patients.

As an initial step in the legislative review, an online engagement process has been launched. All Canadians are invited to read Taking Stock of Progress: Cannabis Legalization and Regulation in Canada and to share their views via the online questionnaire or through written feedback until November 21, 2022.

  1. First Nations, Inuit, and Métis peoples are invited to read and provide feedback by November 21, 2022, on the Summary from Engagement with First Nations, Inuit and Métis Peoples.

The Summary outlines what has been heard by Health Canada to date through engagement with First Nations, Inuit and Métis peoples on the Cannabis Act. Feedback on this paper will help confirm if Health Canada has properly understood their perspectives, priorities and concerns related to cannabis.

Quotes

“The work of the Expert Panel will address the ongoing and emerging needs of Canadians while protecting their health and safety. Through this useful, inclusive and evidence-driven review, we will strengthen the Act so that it meets the needs of all Canadians while continuing to displace the illicit market. I look forward to receiving the Panel’s findings.”

The Honourable Jean-Yves Duclos
Minister of Health

“Ensuring that this review is informed by the input of experts and interested partners in many fields, Indigenous partners, as well as individual Canadians, will be essential to the work being done by Mr. Rosenberg and the rest of the Expert Panel. Congratulations to him, and we look forward to the Panel’s Review. Their work will be vital for our Government to continue moving ahead in a responsible way, while also minimizing the health risks associated with cannabis, especially for young Canadians.”

The Honourable Carolyn Bennett
Minister of Mental Health and Addictions and Associate Minister of Health

“I am honoured to be leading the Expert Panel in conducting a thorough, independent review of the Cannabis Act. I look forward to hearing the perspectives of the public, stakeholders, and First Nations, Inuit and Métis peoples through the online engagement process underway.”

Mr. Morris Rosenberg
Chair of the Expert Panel

Quick Facts
  • The Cannabis Act came into force on October 17, 2018, putting in place a new, strictly regulated framework for controlling the sale, possession, production and distribution of cannabis.
  • The Act requires the Minister of Health to conduct a review of the legislation, its administration, and operation three years after coming into force, and for the Minister to table a report on this review in both Houses of Parliament 18 months after the review begins.
  • The legislative review will assess the progress made towards achieving the Act’s objectives, and will evaluate:
    • Impacts on young persons;
    • Progress towards providing adults with access to strictly regulated, lower risk, legal cannabis products;
    • Progress made in deterring criminal activity and displacing the illicit cannabis market;
    • Impacts of legalization and regulation on access to cannabis for medical purposes;
    • Impacts on First Nations, Inuit, and Métis Peoples and communities; and
    • Trends and impact of home cultivation of cannabis for non-medical purposes.
Associated links

SOURCE Health Canada

Success Of Bahamas Cannabis Industry Hinges On Banking Acceptance Says AG

The Bahamas are located in the Caribbean which is a region that is seeing increased cannabis industry activity, and for good reason. After all, it is no secret that the cannabis plant grows very well naturally in the region.

As the island nation’s cannabis industry continues its quest to become a regional industry leader, a major hurdle facing the industry in the Bahamas is banking access. It’s something that elected officials in other Caribbean nations have expressed concerns about, and you can now add the Bahamas’ attorney general to that list. Per Eyewitness News:

Attorney General Ryan Pinder yesterday said that banks need to demonstrate less resistance to the digital asset and cannabis industries, noting that they play a key role in the survivability of those industries.

Pinder spoke with Eyewitness News on the sidelines of the Association of International Bank and Trust Companies (AIBT) Nassau Conference.

The legal cannabis industry in the Bahamas is still very young, with many rules and regulations still being crafted. With that in mind, it will be awhile before the nation’s industry actually comes up against banking access issues in a significant way.

Yet, just the threat of a banking issue has proven to be enough to derail reform and industry efforts in other countries, as cannabis opponents point to it repeatedly in an attempt to delay said efforts.

Hopefully that doesn’t prove to be the case in the Bahamas and that locals will recognize that the cannabis industry is thriving elsewhere despite ongoing international and domestic banking headaches.

Committee Approves Cannabis Regulation Measure In Colombia

The cannabis industry is on the move at the global level, and there are few places on earth where that is as evident as in Colombia. The South American country is undergoing a transformation at a steady pace and taking its rightful spot as an international cannabis powerhouse.

So far, Colombia’s industry is based on the medical cannabis industry. Adult-use legalization is a tougher sell in Colombia due to stigma regarding the ongoing drug war, however, as we previously reported support for regulation is building among Colombia’s citizens.

Support for adult-use regulation is also increasing in political circles as well, as evidenced by a recent vote in Colombia. Per Infobae (translated to English):

This Wednesday, September 14, the First Committee of the House of Representatives approved, in the first debate, the constitutional reform project that seeks to regulate cannabis for adult use in Colombia. Juan Carlos Losada, representative to the Chamber of the Liberal Party, was the author of the project that seeks to become a law of the Republic.

The congressman celebrated this first step on his Twitter account. In the social network he assured that he will send a formal invitation to President Gustavo Petro so that the Government joins the discussion, “since he will be in charge of regulation.”

The successful committee vote is just one of the many hurdles that needs to be overcome in order for adult-use cannabis legalization to become a reality in Colombia. With that being said, it’s still cause for celebration, albeit tempered celebration.

To date the only countries that have legalized cannabis for adult-use at a national level beyond just low-THC cannabis are Uruguay, Canada, and Malta.

Study Finds Benefits For Autism Patients Following Use Of CBD-Rich Cannabis

Cannabidiol (CBD) is arguably the most popular cannabinoid on earth right now, at least among lawmakers. Whereas elected officials are unfortunately still reluctant to reform cannabis laws pertaining to THC in many areas, more and more of them are opening up to CBD reform.

The spread of CBD reform has been paralleled by a rise in CBD research, which is a great thing for patients everywhere. A recent study in Israel found that the use of CBD-rich cannabis may provide benefits to autism patients. Below is more information about it via a news release from NORML:

Tel Aviv, Israel: The administration of CBD-rich cannabis is associated with clinical improvements in adolescents with autism spectrum disorder (ASD), according to data published in the journal Translational Psychiatry.

Israeli researchers evaluated the efficacy of cannabis treatment in a cohort of 82 young people (ages 5 to 25) with ASD. Subjects in the trial consumed whole-plant cannabis extracts (oils with a CBD:THC ratio of 20 to 1) adjunctively over a period of six months. Investigators used a variety of standardized clinical assessments to evaluate patients’ symptoms prior to and immediately following treatment.

They reported, “Our results revealed significant improvements in [the] overall … scores of the ASD participants who completed the 6-month treatment protocol with CBD-rich cannabis. Overall changes were mostly driven by improvements in social communication skills.

“[T]hese findings suggest that treatment with CBD-rich medicinal cannabis can lead to significant improvements in social communication skills of some ASD individuals, particularly those with more severe initial symptoms,” authors concluded. “These positive findings motivate further double-blind placebo-controlled studies for determining the efficacy of treatment with specific cannabis strains and/or synthetic cannabinoids.

The researchers’ findings are consistent with those of numerous other studies demonstrating that the use of either CBD-dominant cannabis or oral extracts is associated with symptom mitigation in adolescents with ASD.

Full text of the study, “Children and adolescents with ASD treated with CBD-rich cannabis exhibit significant improvements, particularly in social symptoms: An open label study,” appears in Translational Psychiatry. Additional information on cannabis and ASD is available from NORML.

Domestic Cannabis Is Finally Coming To New Zealand

New Zealand nearly became the third country to pass an adult-use cannabis legalization measure back in 2020. The referendum measure failed by just over 2% of the vote. Had the referendum succeeded, New Zealand would have become the first country on earth to pass a national cannabis legalization measure at the ballot box versus via legislative action. Unfortunately, it proved to be a missed opportunity.

New Zealand was already home to a medical cannabis program, however, the program was very limited. While that will still largely be the case, there’s at least one component of the country’s medical cannabis program that is going to see improvement in the near future.

Government officials in New Zealand have finally granted permission for domestic medical cannabis cultivation. Per Newshub:

The Ministry of Health has just approved homegrown and manufactured medicines – so Kiwis no longer have to rely on imported medicinal cannabis.

This green gold has been given the green light by health officials to be turned into medicine for Kiwis patients.

“It’s something the whole industry has been working towards,” Helius Therapeutics CEO Carmen Doran said.

New Zealand is currently home to roughly three dozen medical cannabis companies, however, they are all operating on an import/export model. Allowing domestic cultivation will likely prove to be a gamechanger for the nation’s emerging cannabis industry.

Cannabis imports and exports will always play a role in the emerging cannabis industry, and should not be avoided entirely. With that being said, no country’s medical cannabis program will never reach its full potential without allowing some form of domestic cultivation.

Why Are Canadian Doctors Still So Unfamiliar With Medical Cannabis?

Despite what some governments around the world may claim, cannabis does indeed possess tremendous medical value, as proven by a growing number of peer reviewed studies and personal testimonies from suffering patients that have successfully treated their condition(s) with cannabis.

Fortunately, more and more cannabis laws are being reformed around the world which is boosting safe access to medical cannabis. For instance, Canada has had a medical cannabis program for several decades now, and is the only G-7 nation to have a nationwide adult-use law on the books.

For some reason, doctors and medical professionals in Canada are still lagging behind when it comes to knowledge of medical cannabis and related topics. Below is more information about it via a news release from NORML:

Montreal, Canada: Despite the federal government having legalized patients’ access to marijuana two decades ago, most Canadian health care providers acknowledge that they possess little knowledge about medical cannabis and almost none report having received any training about it while in medical school.

Survey data published in the journal BMC Complementary Medicine and Therapies reported that 56 percent of respondents felt either “uncomfortable or ambivalent regarding their knowledge of medical cannabis,” and that only six percent of medical professionals received any formal training about it while attending medical school. (By contrast, 60 percent of respondents said that they had   attended either a workshop or a conference on the topic.) Fewer than one-in-three (27 percent) acknowledged being familiar with the regulations surrounding patients’ access to medical cannabis products.

The results are consistent with numerous other surveys from the United States and abroad finding that health professionals seldom receive any formal training about cannabis and that most lack sufficient understanding of the subject.

Authors concluded: “The majority of HCPs [health care practitioners] received little, if any, formal training in cannabinoid-based medicine in medical school or residency, … and nearly one-third were unfamiliar with the requirements for obtaining CMP [cannabis for medical purposes] in Canada. Respondents endorsed discomfort with their knowledge of MC [medical cannabis.] …. These findings suggest that medical training programs must reassess their curricula to enable HCPs to gain the knowledge and comfort required to meet the evolving needs of patients.”

Full text of the study, “Healthcare practitioner perceptions on barriers impacting cannabis prescribing practices,” appears in BMC Complementary Medicine and Therapies. Additional information is available in NORML’s fact sheet, ‘Health Clinicians Attitudes Toward Cannabis.’